210 related articles for article (PubMed ID: 15917666)
21. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin.
Retzer-Lidl M; Schmid RM; Schneider G
Int J Cancer; 2007 Jul; 121(1):66-75. PubMed ID: 17304504
[TBL] [Abstract][Full Text] [Related]
22. Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity.
Shao T; Zheng Y; Zhao B; Li T; Cheng K; Cai W
Sci China Life Sci; 2014 Oct; 57(10):1011-7. PubMed ID: 25216706
[TBL] [Abstract][Full Text] [Related]
23. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction.
Stork P; Loda M; Bosari S; Wiley B; Poppenhusen K; Wolfe H
Oncogene; 1991 May; 6(5):857-62. PubMed ID: 1646989
[TBL] [Abstract][Full Text] [Related]
24. Survivin expression and its clinical significance in pancreatic cancer.
Lee MA; Park GS; Lee HJ; Jung JH; Kang JH; Hong YS; Lee KS; Kim DG; Kim SN
BMC Cancer; 2005 Oct; 5():127. PubMed ID: 16202147
[TBL] [Abstract][Full Text] [Related]
25. Growth inhibition induced by short hairpin RNA to silence survivin gene in human pancreatic cancer cells.
Shen YM; Yang XC; Song ML; Qin CH; Yang C; Sun YH
Hepatobiliary Pancreat Dis Int; 2010 Feb; 9(1):69-77. PubMed ID: 20133233
[TBL] [Abstract][Full Text] [Related]
26. Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma.
Chen YB; Tu JJ; Kao J; Zhou XK; Chen YT
Arch Pathol Lab Med; 2008 Feb; 132(2):224-31. PubMed ID: 18251581
[TBL] [Abstract][Full Text] [Related]
27. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
[TBL] [Abstract][Full Text] [Related]
28. Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells.
Sarthy AV; Morgan-Lappe SE; Zakula D; Vernetti L; Schurdak M; Packer JC; Anderson MG; Shirasawa S; Sasazuki T; Fesik SW
Mol Cancer Ther; 2007 Jan; 6(1):269-76. PubMed ID: 17237286
[TBL] [Abstract][Full Text] [Related]
29. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
Yie SM; Luo B; Ye NY; Xie K; Ye SR
Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
[TBL] [Abstract][Full Text] [Related]
30. The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma.
Ikeda N; Nakajima Y; Sho M; Adachi M; Huang CL; Iki K; Kanehiro H; Hisanaga M; Nakano H; Miyake M
Cancer; 2001 Aug; 92(3):488-99. PubMed ID: 11505392
[TBL] [Abstract][Full Text] [Related]
31. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
[TBL] [Abstract][Full Text] [Related]
32. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
Qian J; Niu J; Li M; Chiao PJ; Tsao MS
Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
[TBL] [Abstract][Full Text] [Related]
33. [Combinational effects of K-ras and IGF-IR antisense oligodeoxynucleotide on proliferation and apoptosis of human pancreatic cancer Patu8988 cells].
Shen YM; Yang XC; Zhang MH; Shen JK; Sun YH
Ai Zheng; 2008 May; 27(5):496-504. PubMed ID: 18479599
[TBL] [Abstract][Full Text] [Related]
34. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.
Marchese R; Muleti A; Pasqualetti P; Bucci B; Stigliano A; Brunetti E; De Angelis M; Mazzoni G; Tocchi A; Brozzetti S
Pancreas; 2006 Mar; 32(2):171-7. PubMed ID: 16552337
[TBL] [Abstract][Full Text] [Related]
35. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
[TBL] [Abstract][Full Text] [Related]
36. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.
Ohnami S; Matsumoto N; Nakano M; Aoki K; Nagasaki K; Sugimura T; Terada M; Yoshida T
Cancer Res; 1999 Nov; 59(21):5565-71. PubMed ID: 10554036
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
[TBL] [Abstract][Full Text] [Related]
38. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
[TBL] [Abstract][Full Text] [Related]
39. Association of matrilysin mRNA expression with K-ras mutations and progression in pancreatic ductal adenocarcinomas.
Fukushima H; Yamamoto H; Itoh F; Nakamura H; Min Y; Horiuchi S; Iku S; Sasaki S; Imai K
Carcinogenesis; 2001 Jul; 22(7):1049-52. PubMed ID: 11408348
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment.
Zhang M; Yang J; Li F
J Exp Clin Cancer Res; 2006 Sep; 25(3):391-402. PubMed ID: 17167980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
